BioLineRx Ltd, a biopharmaceutical development company, was invited to deliver an oral presentation at the recent 2013 National Education Conference & Gluten-Free Expo, the Celiac Disease Foundation’s annual conference, in Pasadena, California.
Leah Klapper, Ph.D., General Manager, BioLine Innovations Jerusalem, presented BioLineRx’s therapy, BL-7010, for the treatment of celiac, as part of a session entitled Breaking Therapies Beyond the Gluten-Free Diet.
December 7, 2012: Port Charlotte, Florida. Gluten Free Works Inc. announced the launch of its newest online publication, Celiac Disease Today.
In our ongoing efforts to help people get well and stay healthy, living gluten free, Gluten Free Works is proud to distribute the first issue of Celiac Disease Today, a special new monthly e-newsletter for gluten-free support group leaders.
As the name suggests, Celiac Disease Today focuses on the health and wellness aspects of celiac disease, complete with accurate and up-to-date information regarding symptoms, research, diagnosis and (more…)
The Food Allergen Labeling and Consumer Protection Act passed in 2004 and it required the FDA to set gluten-free labeling legislation by 2008, but here we are in October 2012 with no finalized gluten-free labeling legislation. There is now an open petition on the White House website asking the Obama administration to finalize gluten-free labeling now.
Lately, it seems like more and more celebrities and professional athletes are openly talking about going gluten free. Whether it’s due to a diagnosis of celiac disease or a gluten sensitivity, or simply because they want to get healthy, many of them have noted a weight loss as part of the benefits they’ve been seeing. Then why is it, that so many doctors and specialists will dismiss a diagnosis of celiac disease in a patient simply because the patient is not underweight?
In a recent article by Sonia Kupfer, MD, the belief that people with un-diagnosed celiac disease are all underweight is revealed to (more…)
There is no cure for celiac disease. But, there may soon be a new therapy to go along with a gluten-free diet.
A Phase II medical research study to test a potential therapy for people with celiac disease is underway and signing up participants at CeliacTrial.com.
Alessio Fasano, MD. Co-founder of Alba Therapeutics
The investigational drug, Larazotide Acetate, was developed by Alba Therapeutics. It passed Phase I trials and is now being studied to determine how effective it is in different doses and whether side effects develop. Alba Therapeutics was co-founded by celiac disease researcher, Dr. Alessio Fasano, director of the Celiac Disease Center at the University of Maryland.1
The therapy is based on Dr. Fasano’s discovery that tight junctions between cells in the intestine can be opened or closed and that gluten relaxes these junctions. It is this process that leads to gluten improperly crossing into the body, thereby eliciting an immune reaction that leads to inflammation and damage characteristic of celiac disease.
“The reality is that the paracellular space is a gate, not a wall or fence. And if material gets through that space – even if it is only 1 to 5% of what normally travels through the cell – it could be associated with disease.”
-Alessio Fasano, MD1
Dr. Fasano discovered the potentially therapeutic utility of down-regulating intestinal permeability of celiac disease.1 In other words, he discovered that (more…)
Domino’s Pizza recently announced it would offer gluten-free pizza for gluten sensitive customers. Domino’s made it clear that the pizzas used a gluten-free crust, but are manufactured using the same equipment as the other gluten-containing foods and are not safe for people with celiac disease.
Domino’s worked with the National Foundation for Celiac Awareness (NFCA) and received the NFCA’s new, and now suspended, “Amber Designation.” This designation was to tell people that although the ingredients are gluten-free, the product cannot claim that cross contamination does not occur. The “Amber Designation” differed from the NFCA’s existing “Green Designation,” which tells the customer that the product is tested to less than 10 parts per million of gluten. “Amber” was basically a caution sign.
What Did Gluten-Free Watchdog Organizations Say?
The Gluten Intolerance Group (GIG) and other organizations called for a recall of the NFCA’s “Amber Designation.”
The North American Society for the Study of Celiac Disease commented on Domino’s Pizza ‘Gluten-Free’ Crust Announcement as follows,
May is National Celiac Disease Awareness Month, so it seems appropriate to share some medical facts about this autoimmune disease that just might shock you.
These facts come from Dr. Tom O’Bryan who is is a nationally recognized speaker and workshop leader specializing in gluten sensitivity and celiac disease. Dr. O’Bryan’s specialty is in teaching the many manifestations of gluten sensitivity and celiac disease as they occur inside and outside of the (more…)